adesso (ADN1) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Revenue grew 13% year-over-year to €794.3 million in H1 2026, driven by strong organic expansion and sector-specific IT and AI solutions.
EBITDA increased 21% to €45.8 million, with margin improving to 5.8% from 5.4% in H1 2025.
Headcount grew 7–9% to over 11,500 FTEs, supporting expansion across sectors and regions.
Acquisition of omni:us strengthens AI-driven insurance solutions and cross-selling potential.
GenAI business generated €73.7 million in new orders across 72 clients in seven countries.
Financial highlights
Gross profit grew 12% to €663.3 million; personnel costs increased 12% to €550.6 million; material costs up 18% due to higher reliance on third-party suppliers and cloud/AI expenses.
EBITDA margin improved to 5.8% in H1 2026.
Net loss narrowed to €7.2 million (EPS: -€0.87), with Q2 affected by write-downs on goodwill and software (material.one).
Net debt increased to €155.3 million; free cash flow improved but remained negative at -€68.9 million.
Dividend of €0.78 per share paid in June 2026; equity ratio stable at 20.1%.
Outlook and guidance
Full-year 2026 revenue guidance confirmed at €1.6–1.7 billion; EBITDA forecasted at €130–150 million.
Majority of EBITDA expected in H2 due to improved utilization and more working days.
Pipeline and order entry remain strong, with book-to-bill ratio above one and positive outlook for H2.
IT services and software markets expected to grow, with digitalization and AI as key drivers.
Latest events from adesso
- Q1 2026 revenue up 13%, EBITDA up 58%, and net earnings positive amid strong sector growth.ADN1
Q1 2026 - 2025 sales rose 14% to EUR 1.47B, with 30% EBITDA growth and a strong 2026 outlook.ADN1
Q4 2025 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 2025 - Sales and EBITDA grew 12% and 34% in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 2025 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU - Sales up 16% to €631.1m, but negative EPS and EBITDA guidance cut amid margin pressure.ADN1
H1 2024 - Sales up 11% in Q1 2025; margin recovery and stronger H2 earnings expected.ADN1
Q1 2025 TU - 14% sales growth and margin gains in 2024 set the stage for further expansion in 2025.ADN1
H2 2024